Tin tức & Cập nhật

Among prostate cancer patients receiving treatment with the androgen receptor pathway inhibitor (ARPI) apalutamide, those who also use statins appear to have longer overall survival, according to a study.

Women with refractory overactive bladder (OAB) may improve their symptoms by using either intradetrusor onabotulinumtoxinA or combined pharmacotherapy with solifenacin and mirabegron, suggests a study.

First-line treatment with enzalutamide plus radium-223 (Ra223) results in significant improvements in radiological progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the EORTC 1222/PEACE-3 trial have shown.